The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index, and 3 are not checked yet.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Systolic Blood Pressure Intervention Trial, 261 patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately twofold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [261]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results have been interpreted to be generally consistent between the two trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (38,40).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (38).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
Experimental — accuracy not yet measuredIn the citing paper
“in which there was a notable 25% relative/0.5% absolute reduced risk per year of cardiovascular morbidity and mortality with intensive (<120 mm Hg) as compared with standard (<140 mm Hg) systolic blood pressure control in patients with hypertension and high cardiovascular risk.71”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [71]
In the citing paper
“This graded approach is based on evidence from multiple meta-analyses and individual RCTs, which show a consistent and graded reduction in CVD risk in response to reductions in TC and LDL-C levels. 61-71”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“The primary composite outcome of myocardial infarction (MI), coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a target systolic blood pressure of < 120 mmHg decreases cardiovascular event rates by 25% in high-risk patients, although people with diabetes were excluded from this trial (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Of note, the ACCORD BP and SPRINT trials targeted a similar systolic blood pressure < 120 mmHg, but in contrast to SPRINT, the primary composite cardiovascular end point was nonsigni fi cantly reduced in ACCORD BP.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The achieved systolic blood pressures in the trial were 121 mmHg and 136 mmHg in the intensive versus standard treatment group, respectively.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular bene fi t of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The results have been interpreted to be generally consistent between both trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,698
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Self-citationHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Research works printed but not linked: 3
- 10.1016/s0140-6736(05)70151-3 · DOI
- Franklin SS, 1999, Pathol Biol (Paris), 47, 594
- Nwankwo T, 2013, NCHS Data Brief, 133, 1
Cited by
Sorted by citations
Items 901–1,000 of 1,036
Transporting experimental results with entropy balancing
Josey, K. P., Berkowitz, S. A., Ghosh, D., & Raghavan, S. (2021) · Statistics in Medicine · doi:10.1002/sim.9031 · Cited by 51
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease
Juraschek, S. P., Hu, J., Cluett, J., Ishak, A. M., Mita, C., Lipsitz, L. A., Appel, L. J., Beckett, N. S., Coleman, R. L., Cushman, W. C., et al. (2023) · JAMA · doi:10.1001/jama.2023.18497 · Cited by 51
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 55
Wu, C., Smit, E., Peralta, C. A., Sarathy, H., & Odden, M. C. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14816 · Cited by 51
Learning What We Didn’t Know — The SPRINT Data Analysis Challenge
Burns, N. S., & Miller, P. W. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1705323 · Cited by 51
J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets
Kalkman, D. N., Brouwer, T. F., Vehmeijer, J. T., Berger, W. R., Knops, R. E., de Winter, R. J., Peters, R. J. G., & van den Born, B. H. (2017) · Circulation · doi:10.1161/circulationaha.117.030342 · Cited by 51
Treatment of Heart Failure with Preserved Ejection Fraction
Ilieșiu, A. M., & Hodorogea, A. S. (2018) · Advances in experimental medicine and biology · doi:10.1007/5584_2018_149 · Cited by 51
Schiavon, C. A., Ikeoka, D., Santucci, E. V., Santos, R. N., Damiani, L. P., Bueno, P. R. T., de Oliveira, J. D., Torreglosa, C. R., Bersch-Ferreira, Â. C., Miranda, T. A., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12290 · Cited by 51
The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus
Hussain, S. T., & Chowdhury, T. A. (2019) · Drugs · doi:10.1007/s40265-019-1061-4 · Cited by 52
Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops
Bryant, K. B., Moran, A. E., Kazi, D. S., Zhang, Y., Penko, J. M., Ruiz‐Negrón, N., Coxson, P. G., Blyler, C. A., Lynch, K., COHEN, L. P., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051683 · Cited by 51
Amanai, S., Harada, T., Kagami, K., Yoshida, K., Kato, T., Wada, N., & Obokata, M. (2022) · Scientific Reports · doi:10.1038/s41598-021-03974-6 · Cited by 51
Time for a prepublication culture in clinical research?
Lauer, M. S., Krumholz, H. M., & Topol, E. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01177-0 · Cited by 44
Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review
Mohottige, D., Manley, H. J., & Hall, R. K. (2021) · Kidney360 · doi:10.34067/kid.0001942021 · Cited by 50
Blood pressure management for secondary stroke prevention
Kitagawa, K. (2022) · Hypertension Research · doi:10.1038/s41440-022-00908-1 · Cited by 50
Jain, R., Stone, J. A., Agarwal, G., Andrade, J. G., Bacon, S., BAJAJ, H. S., Baker, B., Cheng, G., Dannenbaum, D. A., Gelfer, M., et al. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.220138 · Cited by 50
Inoue, K., Adomi, M., Efthimiou, O., Komura, T., Omae, K., Ōnishi, A., Tsutsumi, Y., Fujii, T., Kondo, N., & Furukawa, T. A. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111538 · Cited by 50
Rodgers, A., Salam, A., Schutte, A. E., Cushman, W. C., de Silva, H. A., Tanna, G. L. D., Grobbee, D. E., Narkiewicz, K., Ojji, D. B., Poulter, N. R., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01744-6 · Cited by 50
Guo, X., Sun, G., Xu, Y., Zhou, S., Song, Q., Li, Y., Ouyang, N., Li, G., Cheng, Z., Ye, N., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01391-1 · Cited by 53
Fan, F., Yuan, Z., Qin, X., Li, J., Zhang, Y., Li, Y., Yu, T., Ji, M., Ge, J., Zheng, M., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08499 · Cited by 50
Cardiovascular Risk Prediction in CKD
Ballew, S. H., & Matsushita, K. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.002 · Cited by 50
Liu, F., Li, J., Chen, J., Hu, D., Li, Y., Huang, J., Liu, X., Yang, X., Cao, J., Shen, C., et al. (2018) · 中国科学通报：英文版 · doi:10.1016/j.scib.2018.05.020 · Cited by 50
Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
Byrd, J. B., Newby, D. E., Anderson, J. A., Calverley, P. M. A., Celli, B. R., Cowans, N. J., Crim, C. C., Martínez, F. J., Vestbo, J., Yates, J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy451 · Cited by 50
Darwin, K. C., Federspiel, J. J., Schuh, B. L., Baschat, A., & Vaught, A. “. J. (2020) · American Journal of Perinatology · doi:10.1055/s-0040-1709465 · Cited by 50
Association of Fatal and Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure
Melgarejo, J. D., Yang, W., Thijs, L., Li, Y., Asayama, K., Hansen, T. W., Wei, F., Kikuya, M., Ohkubo, T., Dolan, E., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14929 · Cited by 50
Bell, K., Doust, J. A., & Glasziou, P. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0310 · Cited by 49
Peng, X., Jin, C., Song, Q., Wu, S., & Cai, J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028762 · Cited by 49
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 55
Diabetes mellitus and hypertension
Oktay, A. A., Aktürk, H. K., & Jahangir, E. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000297 · Cited by 49
Papademetriou, V., Zaheer, M., Doumas, M. N., Lovato, L., Applegate, W. B., Tsioufis, C. P., Mottle, A., Punthakee, Z., Cushman, W. C., & ACCORD Study Group (2016) · American Journal of Nephrology · doi:10.1159/000446122 · Cited by 49
Triple-combination therapy in the treatment of hypertension: a review of the evidence
Düsing, R., Waeber, B., Destro, M., Maia, C. S., & Brunel, P. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.5 · Cited by 49
Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis
Nielsen, O. W., Sajadieh, A., Sabbah, M., Greve, A. M., Olsen, M. H., Boman, K., Nienaber, C. A., Kesäniemi, Y. A., Pedersen, T. R., Willenheimer, R. B., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.021213 · Cited by 49
Recent trends in the prevalence of chronic kidney disease
Hsu, R. K., & Powe, N. R. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000315 · Cited by 49
Hypertension: Overly important but under-controlled
van Kleef, M. E. A. M., & Spiering, W. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317709116 · Cited by 49
Mobula, L. M., Sarfo, F. S., Carson, K. A., Burnham, G. M., Arthur, L., Ansong, D., Sarfo‐Kantanka, O., Plange‐Rhule, J., & Ofori‐Adjei, D. (2018) · Translational Metabolic Syndrome Research · doi:10.1016/j.tmsr.2018.09.001 · Cited by 49
Duan, T., Rajpurkar, P., Laird, D., Ng, A. Y., & Basu, S. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005010 · Cited by 49
RetractedRole of Coronary Artery Calcium for Stratifying Cardiovascular Risk in Adults With Hypertension
Uddin, S. M. I., Mirbolouk, M., Kianoush, S., Orimoloye, O. A., Dardari, Z., Whelton, S. P., Miedema, M. D., Nasir, K., Rumberger, J. A., Shaw, L. J., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12266 · Cited by 49
Faucon, A., Flamant, M., Metzger, M., Boffa, J., Haymann, J., Houillier, P., Thervet, É., Vrtovsnik, F., Stengel, B., Géri, G., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.06.017 · Cited by 49
Katz, D. H., & Gavin, M. C. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201908060 · Cited by 49
Rao, S. G., Segar, M. W., Bress, A. P., Arora, P. K., Vongpatanasin, W., Agusala, V., Essien, U. R., Correa, A., Morris, A. A., de Lemos, J. A., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6566 · Cited by 49
Rahman, F., McEvoy, J. W., Ohkuma, T., Marre, M., Hamet, P., Harrap, S., Mancia, G., Rodgers, A., Selvin, E., Williams, B., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12414 · Cited by 48
Mottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
An Update on Current Therapeutic Options in IgA Nephropathy
Lim, R. S., Yeo, S. C., Barratt, J., & Rizk, D. V. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040947 · Cited by 48
Labarthe, D. R., Goldstein, L. B., Antman, E. M., Arnett, D. K., Fonarow, G. C., Alberts, M. J., Hayman, L. L., Khera, A., Sallis, J. F., Daniels, S. R., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000410 · Cited by 48
Medical treatment of stable angina: A tailored therapeutic approach
Manolis, A. J., Poulimenos, L. E., Ambrosio, G., Kallistratos, M. S., López-Sendón, J., Dechend, R., Mancia, G., & Camm, A. J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.150 · Cited by 48
Chade, A. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08319 · Cited by 48
Prognostic Value of Long-Term Blood Pressure Changes in Patients with Chronic Heart Failure
Schmid, F. A., Schlager, O., Keller, P., Seifert, B., Huang, R., Fröhlich, G., Lüscher, T. F., Ruschitzka, F. T., & Enseleit, F. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.805 · Cited by 48
Selvaraj, S., Claggett, B. L., Shah, S. J., Anand, I. S., Rouleau, J. L., Desai, A. S., Lewis, E. F., Pitt, B., Sweitzer, N. K., Pfeffer, M. A., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1060 · Cited by 48
Dekker, M. J. E., Konings, C. J. A. M., Canaud, B., Carioni, P., Guinsburg, A. M., Madero, M., van der Net, J., Raimann, J. G., SANDE, F. M. V. D., Stuard, S., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy095 · Cited by 48
Hypertension Management at Older Age: An Update
Pinto, R. D., & Ferri, C. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0290-z · Cited by 48
Xiong, X., Wang, P., Duan, L., Liu, W., Chu, F.-Y., Li, S., Li, X., Su, K., You, H., & Xing, Y. (2019) · Phytomedicine · doi:10.1016/j.phymed.2019.152849 · Cited by 48
Personalized Medicine and the Treatment of Hypertension
Melville, S., & Byrd, J. B. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0921-3 · Cited by 48
Risk of ESKD in Older Live Kidney Donors with Hypertension
Ammary, F. A., Luo, X., Muzaale, A. D., Massie, A. B., Crews, D. C., Waldram, M. M., Qadi, M. A., Garonzik‐Wang, J., Henderson, M. L., Brennan, D. C., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14031118 · Cited by 48
2019 AHA/ACC Clinical Performance and Quality Measures for Adults With High Blood Pressure
Casey, D. E., Thomas, R. J., Bhalla, V., Commodore-Mensah, Y. Y., Heidenreich, P. A., Kolte, D. S., Muntner, P., Smith, S. C., Spertus, J. A., Windle, J. R., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.001 · Cited by 48
Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation
Ell, P., Martin, J. M., Cehic, D., Ngo, D. T. M., & Sverdlov, A. L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00868-7 · Cited by 48
Brettler, J. W., Arcila, G. P. G., Aumala, T., Best, A., Campbell, N. R. C., Cyr, S., Gamarra, Á., Jaffe, M. G., la Rosa, M. J. D., Figueredo, J. I. M., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100223 · Cited by 48
Scheen, A. J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.016 · Cited by 47
Maniero, C., Lopuszko, A., Papalois, K.-B., Gupta, A. K., Kapil, V., & Khanji, M. Y. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac163 · Cited by 47
Managing hypertension in type 2 diabetes mellitus
Horr, S. E., & Nissen, S. E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.001 · Cited by 47
Human hypertension, sympathetic activity and the selfish brain
Hart, E. C. (2016) · Experimental Physiology · doi:10.1113/ep085775 · Cited by 47
Management of Stable Angina – Current Guidelines: A Critical Appraisal
Thadani, U. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6681-2 · Cited by 47
Morawski, K., Ghazinouri, R., Krumme, A. A., McDonough, J., Durfee, E., Oley, L. A., Mohta, N. S., Juusola, J. L., & Choudhry, N. K. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.11.007 · Cited by 47
Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk
Ku, E., Bakris, G. L., Johansen, K. L., Lin, F., Sarnak, M. J., Campese, V. M., Jamerson, K., Gassman, J., Smogorzewski, M. J., & Hsu, C. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017010040 · Cited by 47
Cardiovascular risk after hospitalisation for unexplained syncope and orthostatic hypotension
Yasa, E., Ricci, F., Magnusson, M., Sutton, R., Gallina, S., Caterina, R. D., Melander, O., & Fedorowski, A. (2017) · Heart · doi:10.1136/heartjnl-2017-311857 · Cited by 47
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
Dargad, R. R., Prajapati, M. R., Dargad Rohit, R., & Parekh, J. D. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.01.002 · Cited by 47
2018 Guidelines on the management of diabetic patients. A position of Diabetes Poland
Diabetology, C. (2018) · Clinical Diabetology · doi:10.5603/dk.2018.0001 · Cited by 47
Blood Pressure and Development of Cardiovascular Disease in Koreans With Type 2 Diabetes Mellitus
Kim, M. K., Han, K., Koh, E. S., Kim, E. S., Lee, M., Nam, G. E., & Kwon, H. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12160 · Cited by 47
Spence, J. D. (2019) · Brain Sciences · doi:10.3390/brainsci9020021 · Cited by 47
Lacson, R. C., Baker, B., Suresh, H., Andriole, K. P., Szolovits, P., & Lacson, E. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy049 · Cited by 47
Rousan, T. A., & Thadani, U. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.26.1 · Cited by 47
Pulse Pressure: An Emerging Therapeutic Target for Dementia
Levin, R., Carnegie, M. H., & Celermajer, D. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00669 · Cited by 48
Marcum, Z. A., Cohen, J. B., Zhang, C., Derington, C. G., Greene, T., Ghazi, L., Herrick, J. S., King, J. B., Cheung, A. K., Bryan, R. N., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.45319 · Cited by 47
Pati, P., Fulton, D. J., Bagi, Z. A., Chen, F., Wang, Y., Kitchens, J., Cassis, L. A., Stepp, D. W., & Rudic, R. D. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06194 · Cited by 47
Parati, G., Ochoa, J. E., Bilo, G., & Zanchetti, A. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.08216 · Cited by 48
Wang, J., Chen, Y., Xu, W., Lu, N., Cao, J., & Yu, S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0215362 · Cited by 45
Blood Pressure Control and the Association With Diabetes Mellitus Incidence
Roumie, C. L., Hung, A. M., Russell, G. B., Basile, J., Kreider, K. E., Nord, J. W., Ramsey, T., Rastogi, A., Sweeney, M. E., Tamariz, L. J., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12572 · Cited by 46
Zhang, Z., Navarese, E. P., Zheng, B., Meng, Q., Liu, N., Ge, H., Pan, Q., Yu, Y., & Ma, X. (2020) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12418 · Cited by 46
Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events
Bress, A. P., Greene, T., Derington, C. G., Shen, J., Xu, Y., Zhang, Y., Ying, J., Bellows, B. K., Cushman, W. C., Whelton, P. K., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.058 · Cited by 46
Dependable approaches to hypertension management: A review
Elendu, C., Amaechi, D. C., Elendu, T. C., Amaechi, E. C., & Elendu, I. D. (2024) · Medicine · doi:10.1097/md.0000000000038560 · Cited by 46
Dong, B., Zhao, Y., Wang, J., Lu, C., Chen, Z., Ma, R., Bi, H., Wang, J., Wang, Y., Ding, X., et al. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2403645 · Cited by 46
Drug Therapy for Stable Angina Pectoris
Rousan, T. A., Mathew, S. T., & Thadani, U. (2017) · Drugs · doi:10.1007/s40265-017-0691-7 · Cited by 46
Celler, B. G., Le, P. N., Basilakis, J., & Eliathamby Ambikairajah, A. (2017) · Physiological Measurement · doi:10.1088/1361-6579/aa6b7e · Cited by 46
Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy
Yogasundaram, H., Kim, D., Oudit, O., Thompson, R. B., Weidemann, F., & Oudit, G. Y. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.04.015 · Cited by 46
Xanthopoulos, A. V., Triposkiadis, F. K., & Starling, R. C. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.01.001 · Cited by 46
Hatleberg, C. I., Ryom, L., Monforte, A. D., Fontas, É., Reiss, P., Kirk, O., El‐Sadr, W., Phillips, A. N., Wit, S. D., Dabis, F., et al. (2018) · HIV Medicine · doi:10.1111/hiv.12639 · Cited by 46
Self-citationMorning Home Blood Pressure and Cardiovascular Events in Japanese Hypertensive Patients
Kario, K., Iwashita, M., Okuda, Y., Sugiyama, M., Saito, I., Kushiro, T., Teramukai, S., & Shimada, K. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11388 · Cited by 46
Kobalava, Z. D., Конради, А. О., Nedogoda, S. V., Arutyunov, G. P., Баранова, Е. И., Барбараш, О. Л., Вадимовна, В. С., Galyavich, A. S., Глезер, М. Г., Drapkina, O. M., et al. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-12-131-142 · Cited by 46
Unattended Versus Attended Blood Pressure Measurement
Salvetti, M., Paini, A., Aggiusti, C., Bertacchini, F., Stassaldi, D., Capellini, S., Ciuceis, C. D., Rizzoni, D., Gatta, R., Rosei, E. A., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12187 · Cited by 46
Sakamoto, M., Matsutani, D., Minato, S., Tsujimoto, Y., Kayama, Y., Takeda, N., Ichikawa, S., Horiuchi, R., Utsunomiya, K., & Nishikawa, M. (2019) · Diabetes Care · doi:10.2337/dc18-1953 · Cited by 46
Marchesan, L. B., & Spritzer, P. M. (2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.11.034 · Cited by 46
Gijón‐Conde, T., Sánchez-Martínez, M., Graciani, A., de la Cruz, J. J., López‐García, E., Ortolá, R., Rodríguez‐Artalejo, F., & Banegas, J. R. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002065 · Cited by 46
Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT
Nuyujukian, D. S., Koška, J., Bahn, G., Reaven, P. D., Zhou, J. J., & VADT Investigators (2020) · Diabetes Care · doi:10.2337/dc19-2540 · Cited by 46
Yamada, M. H., Fujihara, K., Kodama, S., Sato, T., OSAWA, T., Yaguchi, Y., Yamamoto, M., Kitazawa, M., Matsubayashi, Y., Yamada, T., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2252 · Cited by 46
Watanabe, H., Martini, A. G., Brown, R. I., Liang, X., Medrano, S., Goto, S., Narita, I., Arend, L. J., Sequeira-Lόpez, M. L. S., & Gómez, R. A. (2021) · JCI Insight · doi:10.1172/jci.insight.154337 · Cited by 46
Longitudinal Patterns of Change in Systolic Blood Pressure and Incidence of Cardiovascular Disease
Petruski‐Ivleva, N., Viera, A. J., Shimbo, D., Muntner, P., Avery, C. L., Schneider, A. L. C., Couper, D. J., & Kucharska‐Newton, A. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06769 · Cited by 46
Hypertension and Target Organ Damage: Don’t Believe Everything You Think!
Mensah, G. A. (2016) · Ethnicity & Disease · doi:10.18865/ed.26.3.275 · Cited by 46
Cunningham, E. L., Todd, S. A., Passmore, P., Bullock, R., & McGuinness, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004034.pub4 · Cited by 45
Hang, F., Chen, J., Wang, Z., Zheng, K., & Wu, Y. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01670-6 · Cited by 45
Liu, L., Xie, X., Pan, Y., Wang, A., Wei, Y., Liu, J., Nie, X., Liu, D., Zhao, Z., Wang, P., et al. (2023) · BMJ · doi:10.1136/bmj-2023-076448 · Cited by 45
Hypertension in Chronic Glomerulonephritis
Ihm, C. (2015) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2015.13.2.41 · Cited by 45
Scheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.12.010 · Cited by 45
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2103-2116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4689591
- OpenAlex
- W3150595609
- Cited by
- 6,325
- References
- 38
- Citations by year
- 2026: 390 · 2025: 449 · 2024: 437 · 2023: 498 · 2022: 523 · 2021: 602 · 2020: 570 · 2019: 694 · 2018: 734 · 2017: 767 · 2016: 613 · 2015: 40
- FWCI
- 522.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR001427, UL1TR000073, UL1TR001064, UL1TR001085, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
- National Institute on Aging (P30AG021332)
- National Heart, Lung, and Blood Institute (HHSN268200900040C, A-HL-13-002-001, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
- National Institute of General Medical Sciences (P30GM103337)
- National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
- National Center for Advancing Translational Sciences (9U54TR000017‐06)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, cardiovascular risk, cardiovascular events, all-cause mortality, adverse events, hypotension, acute kidney injury, non-diabetic patients
- MeSH terms
- Age Factors, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Cause of Death, Female, Goals, Humans, Hypertension, Male, Middle Aged, Risk Factors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
